Legal status in the United States: prescription, compounded, and research-only

Three legal categories, three different stories

Every peptide in active US use sits in one of three boxes, and the box determines what you can buy, where you can buy it, and what risk you are taking.

• FDA-approved drugs — manufactured by named pharmaceutical companies for specific indications. Prescription required. Highest quality, highest cost.
• Compounded medications — prepared by 503A or 503B pharmacies for individual patients. Prescription required. Legal status depends on whether the active ingredient is on the FDA's bulk substance list.
• Research-use-only compounds — sold by chemical suppliers, not for human consumption per their labels. Legally a grey zone; the molecule is not regulated as a drug because it is not being sold as one.

FDA-approved peptides

A small but growing list. These are the only peptides you can get from a regular pharmacy with a regular prescription, billed against insurance.

• Semaglutide (Ozempic, Wegovy, Rybelsus) — Novo Nordisk. T2D, weight management, cardiovascular risk reduction.
• Tirzepatide (Mounjaro, Zepbound) — Eli Lilly. T2D and weight management.
• Tesamorelin (Egrifta) — Theratechnologies. HIV-associated lipodystrophy.
• Bremelanotide / PT-141 (Vyleesi) — Palatin. HSDD in premenopausal women.
• Liraglutide (Saxenda, Victoza) — Novo Nordisk. T2D and weight management.
• Sermorelin (Geref, withdrawn 2008 but compoundable).

Compounded peptides: 503A vs 503B

The 1997 FDA Modernization Act created two compounding categories. The distinction matters because the rules — and the risks — are different.

503A pharmacies compound for individual patients with individual prescriptions. They can use bulk substances from the FDA's approved bulk list. They cannot mass-produce; each prescription is patient-specific.

503B outsourcing facilities can produce larger batches without patient-specific prescriptions and must register with the FDA. They are subject to current Good Manufacturing Practices (cGMP) and inspections. 503B-compounded products are generally higher-quality but also more expensive.

For most of the GLP-1 era (2022–2024), compounded semaglutide and tirzepatide were widely available because both drugs were on the FDA's official drug shortage list. Compounding a drug that is FDA-approved but in shortage is legal under FDCA §503A(b) and §503B. The shortage status is what unlocked the compounding pathway.

The 2024–2025 enforcement shift

In October 2024, the FDA removed tirzepatide from the shortage list. In February 2025, it did the same for semaglutide. The clock started immediately: 503A pharmacies got 60 days to wind down compounded production; 503B facilities got 90 days. Multiple lawsuits followed. The current state is unstable, jurisdiction-dependent, and worth checking before assuming the compounded product you bought last year is still legal to buy this year.

Research-use-only compounds

Most of the rest of the index — BPC-157, TB-500, ipamorelin, CJC-1295, MT-II, GHK-Cu, Selank, Semax, Epitalon, MOTS-c, 5-Amino-1MQ — is sold as 'research use only, not for human consumption'. The label is a legal posture: the seller is not marketing a drug, so they are not regulated as a drug seller.

What that means in practice:

• Buying and possessing for personal research is generally not prosecuted at the federal level. Importing in quantity can attract attention.
• Selling for human use is a different question and is what triggers FDA enforcement.
• Distributing to others — even for free — moves you from possessor to distributor in the eyes of the law.
• State law varies. A few states have explicitly addressed peptides; most have not.

BPC-157 and the FDA bulk list

BPC-157 is a useful case study. In 2023 the FDA placed it in Category 2 of the bulk compounding list (substances that may pose significant safety risks). The effect: 503A pharmacies cannot compound BPC-157 for patient prescriptions. It remains available only through research-use-only channels. The Category 2 placement is not a finding that BPC-157 is unsafe — it is a finding that the data is insufficient to determine safety for compounded use. The distinction matters.

Customs, importation, and personal-use exceptions

FDA's Personal Importation Policy allows individuals to bring small amounts of certain unapproved drugs into the US for personal use, primarily for serious conditions and when no US treatment is available. The policy is narrow, discretionary, and not a blanket permission. International orders of research peptides are regularly intercepted; the practical effect is delay and seizure, not criminal prosecution for typical quantities.

What this is not

This guide is a practical map, not legal advice. The regulatory state is moving and varies by state. If your situation is high-stakes — large quantities, professional licensure at risk, athletic eligibility — get a real lawyer who knows FDA enforcement and your state pharmacy board.